Peking University School of Oncology Beijing Cancer Hospital Beijing 100036 China;
Peking University School of Oncology Beijing Cancer Hospital Beijing 100036 China;
Peking University School of Oncology Beijing Cancer Hospital Beijing 100036 China;
malignant hypercalcemia; zoledronic acid; phase Ⅱ clinical trial;